PSI/EFSPI Vaccines Statistics Workshop

Chair; Ian Hirsch, AstraZeneca A Threshold of Protection Model for Monoclonal Antibody Efficacy Against SARS-CoV-2 Variants. Seth Seegobin, Executive Director of Biostatistics and Head of the Statistics Department of Vaccine and Immune Therapies, AstraZeneca. Winter is coming; forecasting the next season's wave in advance. Federico Francone, Data Science, Associate Director, Vaccine and Immune Therapies, AstraZeneca. Bayesian Statistics for Age Expansion in Vaccines with Example. Scott Patterson, Senior Expert Statistical Scientist, Sanofi Vaccines, Sanofi. 10:30 - 11:00 Coffee break 11:00 - 12:30 Session 2 Chair: Andrea Callegano, GSK Robust (exchangeability) Bayesian methods for vaccines targeting multiple serotypes. Margherita Annaratone, Principal Statistician, GSK Vaccines The validity of test-negative design for assessment of vaccine protection. Prof. Xinxue Liu, Associate Professor of Epidemiology and Health Statistics, University of Oxford. Within-host mathematical models to study antibody kinetics after the prophylactic Ebola vaccine in the Democratic Republic of the Congo. Irene Garcia-Fogeda, Steven Abrams, Stifp Vanhee, Akha Salloum, Benson Ogunins, Stifp Vanhee, Researchers, University of Antwerp, Belgium 12:30 - 14:30 Lunch Break and Poster Session Chair: Falnand in Prophylactic Vaccine Trials, Francois Beckers, Global Head of Vaccines Biostatistical Sciences, Sanofi. Assumption-Lean Strategies for Handling Intercurrent Events in Randomized Trials, Prof. Stiff vansteelandt, University of Gent, Belgium. Coffee break Chair: Falnan Tibaldi, GSK Paradigms for the evaluation of surrogate endpoints and correlates-of-protection: vaccines, the pandemic preparedness, and beyond. Prof. Geert Molenbergis, Professor of Biostatistics, BioStat Universiteit Hassett & KU Leuven, Belgium.	8:50 - 9:00	Welcome
Monoclonal Antibody Efficacy Against SARS-CoV-2 Variants. Seth Seegobin, Executive Director of Biostatistics and riead of the Statistics Department of Vaccine and Immune Therapies, AstraCenees. Winter is coming; forecasting the next season's wave in advance, Federico Francone, Data Science, Associate Director, Vaccine and Immune Therapies, AstraZeneca. Bayesian Statistics for Age Expansion in Vaccines with Example. Scott Patterson, Senior Expert Statistical Scientist, Sanofi Vaccines, Sanofi. 10:30 - 11:00 Coffee break Chair: Andrea Callegaro, GSK Robust (exchangeability) Bayesian methods for vaccines targeting multiple serotypes. Margherita Annaratone, Principal Statistician, GSK Vaccines The validity of test-negative design for assessment of vaccine protection, Prof. Xinxue Liu, Associate Professor of Epidemiology and Health Statistics, University of Oxford. Within-host mathematical models to study antibody kinetics after the prophylactic Ebola vaccine in the Democratic Republic of the Congo. Irene Garcia-Fogeda, Steven Abrams, Stijn Vanhee, Maho Saldum, Benson Ogunjimi, Niel Hens. Researchers, University of Antwerp, Belgium 12:30 - 14:30 Lunch Break and Poster Session Chairs: Honghong Zhou, Moderna Adopting Estimand in Prophylactic Vaccine Trials. Prancois Beckers, Global Head of Vaccines Biostatistical Sciences, Sanofi. Assumption-Lean Strategies for Handling Intercurrent Events in Randomized Trials. Prof. Stijn Vansteelandt, University of Cent. Belgium. 15:30 - 16:00 Coffee break Chair: Fanocis Beckers, Global Head of Vaccines Biostatistical Sciences, Sanofi. Assumption-Lean Strategies for Handling Intercurrent Events in Randomized Trials. Prof. Stijn Vansteelandt, University of Cent. Belgium. Coffee break Chair: Bajain Tibaldi, GSK Paradigms for the evaluation of surrogate endpoints and correlates-of-protection: vaccines, the pandemic preparedness, and beyond. Prof. Geert Molenberghs, Professor of Biostatistics. I-BioStat Universiteit Hasselt & KU Leuven, Belgium.	9:00 - 10:30 Session 1	Chair: Ian Hirsch, AstraZeneca
season's wave in advance. Federico Francone, Data Science, Associate Director, Vaccine and Immune Therapies, AstraZeneca. Bayesian Statistics for Age Expansion in Vaccines with Example. Scott Patterson, Senior Expert Statistical Scientist, Sanofi Vaccines, Sanofi. 10:30 - 11:00 Coffee break 11.00 - 12:30 Session 2 Chair: Andrea Callegaro, GSK Robust (exchangeability) Bayesian methods for vaccines targeting multiple serotypes, Margherita Annaratone, Principal Statistician, GSK Vaccines The validity of test-negative design for assessment of vaccine protection. Prof. Xinxue Liu, Associate Professor of Epidemiology and Health Statistics, University of Oxford. Within-host mathematical models to study antibody kinetics after the prophylactic Ebola vaccine in the Democratic Republic of the Congo. Irene Garcia-Fogeda, Steven Abrams, Stijn Vanhee, Maha Saldoum, Benson Ogunjimi, Niel Hens. Researchers, University of Antwerp, Belgium 12:30 - 14:30 Lunch Break and Poster Session 14:30 - 15:30 Session 3 Chairs: Honghong Zhou, Moderna Adopting Estimand in Prophylactic Vaccine Trials. Francois Beckers, Global Head of Vaccines Biostatistical Sciences, Sanofi. Assumption-Lean Strategies for Handling Intercurrent Events in Randomized Trials. Prof. Stijn Vansteelandt, University of Gent, Belgium. Coffee break Chair: Fabian Tibaldi, GSK Paradigms for the evaluation of surrogate endpoints and correlates-of-protection: vaccines, the pandemic preparedness, and beyond. Prof. Geert Molenberghs, Professor of Biostatistics, BioStat Universiteit Hasselt & KU Leuver, Belgium.		Monoclonal Antibody Efficacy Against SARS- CoV-2 Variants. Seth Seegobin, Executive Director of Biostatistics and Head of the Statistics Department of Vaccine and Immune
Vaccines with Example. Scott Patterson, Senior Expert Statistical Scientist, Sanofi Vaccines, Sanofi. 10:30 - 11:00 Coffee break 11.00 - 12:30 Session 2 Chair: Andrea Callegaro, GSK Robust (exchangeability) Bayesian methods for vaccines targeting multiple serotypes. Margherita Annaratone, Principal Statistician, GSK Vaccines The validity of test-negative design for assessment of vaccine protection. Prof. Xinxue Liu, Associate Professor of Epidemiology and Health Statistics, University of Oxford. Within-host mathematical models to study antibody kinetics after the prophylactic Ebola vaccine in the Democratic Republic of the Congo. Irene Garcia-Fogeda, Steven Abrams, Stijn Vanhee, Maha Salloum, Benson Ogunjimi, Niel Irlens. Researchers, University of Antwerp, Belgium 12:30 - 14:30 Lunch Break and Poster Session 14:30 - 15:30 Session 3 Chairs: Honghong Zhou, Moderna Adopting Estimand in Prophylactic Vaccine Trials. Francois Beckers, Global Head of Vaccines Biostatistical Sciences, Sanofi. Assumption-Lean Strategies for Handling Intercurrent Events in Randomized Trials. Prof. Stijn Vansteelandt, University of Gent, Belgium. 15:30 - 16:00 Coffee break Chair: Fabian Tibaldi, GSK Paradigms for the evaluation of surrogate endpoints and correlates-of-protection: vaccines, the pandemic preparedness, and beyond. Prof. Geert Molenberghs, Professor of Biostatistics, I-Biostat Universiteit Hasselt & KU Leuven, Belgium.		season's wave in advance. Federico Francone, Data Science, Associate Director, Vaccine and
Chair: Andrea Callegaro, GSK Robust (exchangeability) Bayesian methods for vaccines targeting multiple serotypes. Margherita Annaratone, Principal Statistician, GSK Vaccines The validity of test-negative design for assessment of vaccine protection. Prof. Xinxue Liu, Associate Professor of Epidemiology and Health Statistics, University of Oxford. Within-host mathematical models to study antibody kinetics after the prophlactic Ebola vaccine in the Democratic Republic of the Congo. Irene Garcia-Fogeda, Steven Abrams, Stijn Vanhee, Maha Salloum, Benson Ogunjimi, Niel Hens. Researchers, University of Antwerp, Belgium 12:30 - 14:30 Lunch Break and Poster Session 14:30 - 15:30 Session 3 Chairs: Honghong Zhou, Moderna Adopting Estimand in Prophylactic Vaccine Trials. Francois Beckers, Global Head of Vaccines Biostatistical Sciences, Sanofi. Assumption-Lean Strategies for Handling Intercurrent Events in Randomized Trials. Prof. Stijn Vansteelandt, University of Gent, Belgium. 15:30 - 16:00 Coffee break Chair: Fabian Tibaldi, GSK Paradigms for the evaluation of surrogate endpoints and correlates-of-protection: vaccines, the pandemic preparedness, and beyond. Prof. Geert Molenberghs, Professor of Biostatistics, I-BioStat Universiteit Hasselt & KU Leuven, Belgium.		Vaccines with Example. Scott Patterson, Senior Expert Statistical Scientist, Sanofi Vaccines,
Robust (exchangeability) Bayesian methods for vaccines targeting multiple serotypes. Margherita Annaratone, Principal Statistician, GSK Vaccines The validity of test-negative design for assessment of vaccine protection. Prof. Xinxue Liu, Associate Professor of Epidemiology and Health Statistics, University of Oxford. Within-host mathematical models to study antibody kinetics after the prophylactic Ebola vaccine in the Democratic Republic of the Congo. Irene Garcia-Fogeda, Steven Abrams, Stijn Vanhee, Maha Salloum, Benson Ogunjimi, Niel Hens. Researchers, University of Antwerp, Belgium 12:30 - 14:30 Lunch Break and Poster Session Chairs: Honghong Zhou, Moderna Adopting Estimand in Prophylactic Vaccine Trials. Francois Beckers, Global Head of Vaccines Biostatistical Sciences, Sanofi. Assumption-Lean Strategies for Handling Intercurrent Events in Randomized Trials. Prof. Stijn Vansteelandt, University of Gent, Belgium. Coffee break Chair: Fabian Tibaldi, GSK Paradigms for the evaluation of surrogate endpoints and correlates-of-protection: vaccines, the pandemic preparedness, and beyond. Prof. Geert Molenberghs, Professor of Biostatistics, I-BioStat Universiteit Hasselt & KU Leuven, Belgium.	10:30 - 11:00	Coffee break
Robust (exchangeability) Bayesian methods for vaccines targeting multiple serotypes. Margherita Annaratone, Principal Statistician, GSK Vaccines The validity of test-negative design for assessment of vaccine protection. Prof. Xinxue Liu, Associate Professor of Epidemiology and Health Statistics, University of Oxford. Within-host mathematical models to study antibody kinetics after the prophylactic Ebola vaccine in the Democratic Republic of the Congo. Irene Garcia-Fogeda, Steven Abrams, Stijn Vanhee, Maha Salloum, Benson Ogunjimi, Niel Hens. Researchers, University of Antwerp, Belgium 12:30 - 14:30 Lunch Break and Poster Session Chairs: Honghong Zhou, Moderna Adopting Estimand in Prophylactic Vaccine Trials. Francois Beckers, Global Head of Vaccines Biostatistical Sciences, Sanofi. Assumption-Lean Strategies for Handling Intercurrent Events in Randomized Trials. Prof. Stijn Vansteelandt, University of Gent, Belgium. Coffee break Chair: Fabian Tibaldi, GSK Paradigms for the evaluation of surrogate endpoints and correlates-of-protection: vaccines, the pandemic preparedness, and beyond. Prof. Geert Molenberghs, Professor of Biostatistics, I-BioStat Universiteit Hasselt & KU Leuven, Belgium.		Chair: Andrea Callegaro, GSK
assessment of vaccine protection. Prof. Xinxue Liu, Associate Professor of Epidemiology and Health Statistics, University of Oxford. Within-host mathematical models to study antibody kinetics after the prophylactic Ebola vaccine in the Democratic Republic of the Congo. Irene Garcia-Fogeda, Steven Abrams, Stijn Vanhee, Maha Salloum, Benson Ogunjimi, Niel Hens. Researchers, University of Antwerp, Belgium 12:30 - 14:30 Lunch Break and Poster Session 14:30 - 15:30 Session 3 Chairs: Honghong Zhou, Moderna Adopting Estimand in Prophylactic Vaccine Trials. Francois Beckers, Global Head of Vaccines Biostatistical Sciences, Sanofi. Assumption-Lean Strategies for Handling Intercurrent Events in Randomized Trials. Prof. Stijn Vansteelandt, University of Gent, Belgium. 15:30 - 16:00 Coffee break Chair: Fabian Tibaldi, GSK Paradigms for the evaluation of surrogate endpoints and correlates-of-protection: vaccines, the pandemic preparedness, and beyond. Prof. Geert Molenberghs, Professor of Biostatistics, I-BioStat Universiteit Hasselt & KU Leuven, Belgium.		for vaccines targeting multiple serotypes. Margherita Annaratone, Principal Statistician,
antibody kinetics after the prophylactic Ebola vaccine in the Democratic Republic of the Congo. Irene Garcia-Fogeda, Steven Abrams, Stijn Vanhee, Maha Salloum, Benson Ogunjimi, Niel Hens. Researchers, University of Antwerp, Belgium 12:30 - 14:30 Lunch Break and Poster Session 14:30 - 15:30 Session 3 Chairs: Honghong Zhou, Moderna Adopting Estimand in Prophylactic Vaccine Trials. Francois Beckers, Global Head of Vaccines Biostatistical Sciences, Sanofi. Assumption-Lean Strategies for Handling Intercurrent Events in Randomized Trials. Prof. Stijn Vansteelandt, University of Gent, Belgium. 15:30 - 16:00 Coffee break Chair: Fabian Tibaldi, GSK Paradigms for the evaluation of surrogate endpoints and correlates-of-protection: vaccines, the pandemic preparedness, and beyond. Prof. Geert Molenberghs, Professor of Biostatistics, I-BioStat Universiteit Hasselt & KU Leuven, Belgium.		assessment of vaccine protection. Prof. Xinxue Liu, Associate Professor of Epidemiology and
12:30 - 14:30 Lunch Break and Poster Session Chairs: Honghong Zhou, Moderna Adopting Estimand in Prophylactic Vaccine Trials. Francois Beckers, Global Head of Vaccines Biostatistical Sciences, Sanofi. Assumption-Lean Strategies for Handling Intercurrent Events in Randomized Trials. Prof. Stijn Vansteelandt, University of Gent, Belgium. 15:30 - 16:00 Coffee break Chair: Fabian Tibaldi, GSK Paradigms for the evaluation of surrogate endpoints and correlates-of-protection: vaccines, the pandemic preparedness, and beyond. Prof. Geert Molenberghs, Professor of Biostatistics, I-BioStat Universiteit Hasselt & KU Leuven, Belgium.		antibody kinetics after the prophylactic Ebola vaccine in the Democratic Republic of the Congo. Irene Garcia-Fogeda, Steven Abrams, Stijn Vanhee, Maha Salloum, Benson Ogunjimi, Niel Hens. Researchers, University of Antwerp,
Adopting Estimand in Prophylactic Vaccine Trials. Francois Beckers, Global Head of Vaccines Biostatistical Sciences, Sanofi. Assumption-Lean Strategies for Handling Intercurrent Events in Randomized Trials. Prof. Stijn Vansteelandt, University of Gent, Belgium. 15:30 - 16:00 Coffee break Chair: Fabian Tibaldi, GSK Paradigms for the evaluation of surrogate endpoints and correlates-of-protection: vaccines, the pandemic preparedness, and beyond. Prof. Geert Molenberghs, Professor of Biostatistics, I-BioStat Universiteit Hasselt & KU Leuven, Belgium.		
Trials. Francois Beckers, Global Head of Vaccines Biostatistical Sciences, Sanofi. Assumption-Lean Strategies for Handling Intercurrent Events in Randomized Trials. Prof. Stijn Vansteelandt, University of Gent, Belgium. 15:30 - 16:00 Coffee break 16:00 - 17:00 Session 4 and closing Chair: Fabian Tibaldi, GSK Paradigms for the evaluation of surrogate endpoints and correlates-of-protection: vaccines, the pandemic preparedness, and beyond. Prof. Geert Molenberghs, Professor of Biostatistics, I-BioStat Universiteit Hasselt & KU Leuven, Belgium.	14:30 - 15:30 Session 3	Chairs: Honghong Zhou, Moderna
Intercurrent Events in Randomized Trials. Prof. Stijn Vansteelandt, University of Gent, Belgium. 15:30 - 16:00 Coffee break 16:00 - 17:00 Session 4 and closing Chair: Fabian Tibaldi, GSK Paradigms for the evaluation of surrogate endpoints and correlates-of-protection: vaccines, the pandemic preparedness, and beyond. Prof. Geert Molenberghs, Professor of Biostatistics, I-BioStat Universiteit Hasselt & KU Leuven, Belgium.		Trials. Francois Beckers, Global Head of
16:00 - 17:00 Session 4 and closing Chair: Fabian Tibaldi, GSK Paradigms for the evaluation of surrogate endpoints and correlates-of-protection: vaccines, the pandemic preparedness, and beyond. Prof. Geert Molenberghs, Professor of Biostatistics, I-BioStat Universiteit Hasselt & KU Leuven, Belgium.		Intercurrent Events in Randomized Trials. Prof. Stijn Vansteelandt, University of Gent, Belgium.
Paradigms for the evaluation of surrogate endpoints and correlates-of-protection: vaccines, the pandemic preparedness, and beyond. Prof. Geert Molenberghs, Professor of Biostatistics, I-BioStat Universiteit Hasselt & KU Leuven, Belgium.		
	16:00 - 17:00 Session 4 and closing	Paradigms for the evaluation of surrogate endpoints and correlates-of-protection: vaccines, the pandemic preparedness, and beyond. Prof. Geert Molenberghs, Professor of Biostatistics, I-BioStat Universiteit Hasselt & KU
····	17:00	Drinks